Media coverage about Amgen (NASDAQ:AMGN) has trended somewhat positive recently, according to Accern. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amgen earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 46.8165854469717 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
- Amgen, Goldman Sachs, Micron, Paypal: Fast Money Picks For October 18 (benzinga.com)
- FY2018 EPS Estimates for Amgen Inc. Decreased by Analyst (AMGN) (americanbankingnews.com)
- Amgen Inc. (AMGN) Set to Announce Earnings on Wednesday (americanbankingnews.com)
- Biotech in Focus: Vitality Biopharma Inc (VBIO), Amgen Inc. (AMGN), Celgene Corporation (CELG) – Argus Journal (argusjournal.com)
- Value System: Amgen Looks Undervalued – Seeking Alpha (seekingalpha.com)
Several research firms have recently weighed in on AMGN. Zacks Investment Research lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Monday. Barclays PLC lifted their target price on shares of Amgen from $180.00 to $190.00 and gave the company an “equal weight” rating in a report on Friday, October 13th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $203.00 target price on shares of Amgen in a report on Friday, October 6th. Mizuho reissued a “buy” rating and issued a $198.00 price target on shares of Amgen in a research note on Friday, October 6th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $196.00 price target (up previously from $189.00) on shares of Amgen in a research note on Friday, October 6th. Twelve analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $189.99.
Amgen (AMGN) opened at 184.12 on Friday. The stock’s 50 day moving average price is $184.98 and its 200 day moving average price is $171.46. Amgen has a 12-month low of $133.64 and a 12-month high of $191.10. The stock has a market cap of $134.35 billion, a price-to-earnings ratio of 16.77 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same period last year, the company earned $2.84 EPS. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. Analysts forecast that Amgen will post $12.58 EPS for the current fiscal year.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.19% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Amgen (AMGN) Getting Somewhat Favorable Press Coverage, Report Finds” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://ledgergazette.com/2017/10/20/amgen-amgn-getting-somewhat-favorable-press-coverage-report-finds.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.